Advanced search×

Surgeons and their patients near the end of life.

Timothy G Buchman

Crit Care Med 38(3):995-6 (2010) PMID 20168162

DOI: 10.1097/CCM.0b013e3181d16b68
Version: za2963e q8za9 q8zb7 q8zc6 q8zdd q8ze8 q8zf9 q8zg4

Similar articles you may find interesting…

  1. Early antibiotic administration but not antibody therapy directed against IL-6 improves survival in septic mice predicted to die on basis of...
    Dinesh D Vyas, Pardis P Javadi, ... Craig M CM Coopersmith

    Am J Physiol Regul Integr Comp Physiol 289(4):R1048-53 (2005) PMID 15947070 PMCID 1237117

    We are unable to demonstrate any benefit in similar animals using targeted therapy directed at IL-6....
    View PDF
  2. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex.
    David Neal DN Franz, Jennifer J Leonard, ... Kerry R KR Crone

    Ann Neurol 59(3):490-8 (2006) PMID 16453317

    All lesions exhibited regression and, in one case, necrosis. Interruption of therapy resulted in regrowth of subependymal giant cell astrocytomas in one patient. Resumption of therapy resulted in further regression. Treatment was well tolerated. INTERPRETATION: Oral rapamycin therapy can induce regr...
  3. Discrepancy between neuroimaging findings and clinical phenotype in Alexander disease.
    A A Dinopoulos, J R JR Gorospe, ... T T DeGrauw

    AJNR Am J Neuroradiol 27(10):2088-92 (2006) PMID 17110673

    We present a case of infantile-onset Alexander disease (AD) with a novel glial fibrillary acidic protein mutation but without clinical evidence of neurologic deterioration. Brain MRI studies showed typical AD findings and increasing size of frontal cavitations. Serial proton MR spectroscopy demonstr...